Skip to content
Wahlster – Managing the Breathing Brain episode artwork

Nov 1, 2023 1 hr 1 min

Wahlster – Managing the Breathing Brain

from Maryland CC Project

Dr. Sarah Wahlster is an associate professor of neurology at University of Washington in Seattle. The focus of her lecture is on mechanical ventilation in patients with neurologic disease.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Wahlster – Managing the Breathing Brain

0:00 1:01:49
of matches

Transcript Auto-generated, may contain errors

Thank you all for joining us today for Critical Care Grand Realms. As some of you may have heard the chatter before we got started, this is Dr. Sarah Walster, and she's an associate professor of neurology at University of Washington in Seattle. I was fortunate to get introduced to her through Nick Morris, who really told me this is an amazing topic and you have to have this person come speak here. And this is really going to be something that's so interesting to our fellows and our faculty. Dr. Walster and I had to change the timing of the talk, and so she was actually scheduled for last year, and I felt so disappointed, like, oh man, we're maybe not going to be able to get her back. So I'm just absolutely giddy and excited to finally have her here. So Dr. Walster, thank you so much for being here today and for...

for sharing this talk on managing the breathing brain. I'm just absolutely so excited to finally get to hear about this. And Nick, I didn't mean to step on your toes. I didn't see you on it first, but thank you for making the suggestion in this introduction and for bringing Dr. Wallster here to share with us for the critical care curriculum.

No problem. I got caught up in clinical care as happens, but thanks so much for coming. Just as a brief personal direction. So Sarah was my chief resident when I was a trainee at Mass General, and I learned a tremendous amount from her and continue to do so. So I'm really excited about this talk. And Sarah, I think, has kind of taken on an interest in some of the areas of neurocritical care that are...

are really paramount to taking care of patients, but neglected in terms of the research interest involved. And I think she's kind of leading the way and thinking about some of the brain-lung interactions that we deal with every day, but there's not a lot of guidance out there. So Sarah's going to give us some guidance in this area. So thanks so much, Sarah. Awesome. Thanks, Andrea and Nick both for the kind introduction. I'm super excited and honored to be here, and thanks for having me back again, despite that initial cancellation. Nick's one of my favorite colleagues ever, and you guys are all so lucky to work with him. And I hope that sometime I can come in person. Nick's definitely also participated a lot in RCL conferences, so I'm super happy to be here today. This is one of my favorite topics, and I'll mainly focus on mechanical ventilation and acute brain injury. It's different. I have no complex interests or relevant financial disclosures. I receive a couple of institutional grants, and I'm also a PI for an NIH-funded trial on subarachnoid hemorrhage. I'm a side PI for the VentiBrain Study, which will be mentioned in this talk, but unfunded.

So yes, mechanical ventilation with acute brain injury are a few things that are unique. And actually just looking at larger mechanical ventilation cohorts, it's pretty notable that there's actually a substantial proportion of patients with severe acute brain injury that comprise patients who need mechanical ventilation worldwide. But despite that, it's kind of depending what papers you look at, it's usually 20, 25 percent, sometimes even a little higher. But despite that, the evidence for how to manage this population is very scarce. And these patients are often underrepresented in trials and often actually excluded, often for concerns around perfusion of the brain or elevated ICP. And I'll highlight that a little more. But unfortunately, that leaves us a little bit in a data-free zone.

And again, patients that have elevated ICPs or concerns for diminished perfusion or are at risk for perfusion-related events are usually, again, there's just no good data in terms of or guidance on what to do. Some unique considerations are that because of these concerns, especially around ICP, ventilator settings, NABG targets may have to be different. And some patients may be done at all. And I think that is a little bit of this problem with patients being excluded from these trials because some may apply this data to these patients without really thinking about the unique considerations. Others may be hesitant to apply proven...

therapies with good evidence and withhold it, and that may also not be ideal. I'll briefly touch a little on brain-lung crosstalk. The brain and lung, there are many bidirectional and intricate pathways in which the brain and lung and critically ill patients influence each other. And then I'll highlight some areas of conflict that we may run into when managing patients with acute brain injury, especially those with lung injury and ARDS. And then I'll speak a little bit about the challenge of liberating patients with mechanical ventilation and predicting excavation success as well as the optimal timing of tracheosity. So I'll get started with vent settings, ABG targets, brain lung connections, and then excavation trait decisions. So in general, just some special consideration.

And again, not a lot of this is guided by data. But for example, just talking about the event mode that patient should be in. And there's actually no direct good trials. I think there's always a little bit of selection based on indication, and there's always rationale. So for example, if the ICP needs to be controlled, if there's need for acid-base control, or just vent synchrony or lung injury controlled mode is used to take control of these. However, many patients are intubated for impaired airway protection, but actually have a fairly intact respiratory drive. Respiratory drive is often lower down in the brainstem, and those patients can often just be in spontaneous modes. And again, what I have found in speaking to colleagues and working at different places is that practice is often institutional. I would say here at Harborview, we're kind of an assist-controlled place, and everyone is on assist-controlled as a default. And often when patients are on pressure-score ventilation, we rest them at night. And it's something...

you know, when Nick and I trained, we often had patients just on pressure support ventilation. And so I've usually, especially when there's really weird dyssynchronies and you end up sedating the patient more and the patient can tolerate it from an oxygenation standpoint, actually try to switch to spontaneous modes. And I find that in some cases, it decreases the need for sedation. The patients are more comfortable. It's less of a stimulator in patients that have some parasympathetic, sorry, sympathetic hyperactivity. But again, there's no clear data. And I've seen a lot of different opinions and preferences. There's some that's saying, you know, it's more physiologic, you work your breathing muscles. There's others that are saying, you know, you can do recruit. And so again, there are more data that's needed. And it doesn't entitle all these peeps, you know.

uh you know trying to you know By driving pressure, kind of get, you know, the right driving pressure or tetrate 2P plat. Those may affect ICP mostly by impacting PCO2, but also by just changes and venous return from the brain. In terms of PO2 targets, both hypoxia and hyperoxia in various styles have been shown to be detrimental. So likely the PO2 targets needed and the guidelines actually addressed that have to be a little higher in our patients. We don't know exactly where the end of that U-shape curves are and what the goal should be. But there is this widespread opinion that an acutely hypermetabolic injured brain may need a slightly higher PO2 than what most, for example, ARDS protocols do. Here on the right is an image from a recent study.

by Kiara-Raba, locating patients in cardiac arrest. And there are some studies also in subarachnoid hemorrhage that kind of show that both on the lower and the higher end, on the lower end, presumably due to secondary brain injury, due to worsening hypoxic injury, and on the higher end, probably due to... oxygen radicals. But yes, there is a U-shape somewhere, and the exact thresholds remain to be established, and there's likely also some individualized thresholds, depending on the type of brain injury and the extent of the brain injury in each individual patient. After some promising results in Boost 2, the Boost 3 trial is underway, looking at a PBTO2 and ICP-guided approach, and oxygen delivery to the brain is also a topic. The Sahara trial is another trial. There's several trials looking at transfusion practices and hemoglobin goals. I'm a bit of a skeptic, personally, just seeing that many of these trials in the general critical literature haven't panned out, but specifically in patients, for example, with cerebral vasospasm, transfusion used to be part of the Triple H, and so this is being more...

investigated. In terms of PCO2 targets, I think that's a key value that all of us neurointensives pay great attention to because it's such a powerful mediator of the cerebral vasculature and high PCO2 causes vasodilitation, which can actually, or is thought to in some ways, enhance perfusion of the brain, but can also contribute to elevated ICPs. Just in terms of looking at outcomes, and, you know, this is just one publication summarizing many studies about both hyper and hypocapnia have been associated with worse outcomes. I think it's always kind of a little bit of a trade-off between ICP and perfusion. If you have patients with really high ICPs, a trauma patient or someone that has bad, you know, cerebral edema and swelling.

Having higher PCO2 may be detrimental. That being said, again, that effect on perfusion may be a good one. It was actually recently the TAME trial that published in cardiac arrest patients looking at PCO2 goals and a slightly higher target range with the hope that that would enhance perfusion. Unfortunately, it did not show an outcome benefit. There used to be this widespread...

practice of hyperventilating neuropatients. And it's still pretty commonly done in the operating room setting because it's a very short-term powerful intervention to lower ICP in a setting of acute crisis. However, longer-term hyperventilation is thought to be harmful because firstly, the effect is lost after a couple hours. You can get rebound ICP crisis. So I'm going from hypo to normocardia. And also just hypocarbia kind of in the kind of, you know, 20s range can cause several basic constrictions and infarcts as well. So it's a...

trade-off probably keeping things in a normal range, but in some patients with really high ACPs for all the kind of deteriorate therapies I've thrown at them, it may be worth targeting a slightly lower range, kind of 30 to 35. And again, a lot of places, cardiac arrest protocols have a slightly kind of on the higher side, PCO2. A couple of years ago, there was a... consensus, international consensus panel led by Kiara Robba, who's pioneered a lot of that work, and Robert Stevens from Hopkins, who basically looked at just what is there in terms of the data. And I think really what they did is they beautifully highlighted a lot of the evidence and data gaps and acknowledged that there was all very weak evidence when there were strong recommendations. There was still based on no evidence, very little evidence. And they did acknowledge that most of their recommendations were mostly good practice statements. And, you know, they recommended kind of classical things that it's worth considering to base with GCS SN8, although that's mostly based on the TBI literature. And it's some literature that, you know, says that maybe you shouldn't just blindly go based on GCS and some controversy around that.

They were unable to comment really on non-invasive ventilation. And then they did recommend a slightly higher, or actually a substantially higher PO2 threshold for neuro patients, patients with brain injury. Recommended kind of, you know, keeping PCA2 in a normal range. Were a little vague about, or a little cautious about therapeutic hyperventilation. Recommended it only in the short term. And then said, you know, PE, LPB prone positioning, you know, one should utilize as in any other ICU patient if there's no concern for elevated ICP. And then they did say that they would be unable to provide any recommendations for those with elevated ICP. So I think the big gray zone and uncertainty is for those patients that have ARDS and need these treatments, but also are in a window where there's...

swelling, and there's a concern for increased ICP and potential herniation. So those are the guidelines. Let's look at the practices. There was a survey, and it's not a few years old, but there was an ESICM survey in 2018 to 2019 looking at around 687 respondents. They were mostly intensivist anesthesiologists. And less than half, 40% reported having a protocol, a standard protocol specifically for brain injury patients, and only a third reported having a weaning protocol. And mostly protocols were there for TBI. And then just looking at the use of various tidal volumes, it's interesting because just...

And the kind of 150 to 300 range, you know, most reported using six to eight CCs, you know, about a third said that they would, you know, consider using four to six CCs. But looking at the really, you know, moderate to severe ARDS range, actually only 53% reported being comfortable using four to six CCs. The highest PEEP, up to 41% were comfortable using a PEEP of 15 in brain-generated patients. And then in those with ICP concerns, it was the highest that most were willing to go to, it was 10 or the highest that people were reported being willing to utilize. 69% saying that they're comfortable utilizing recruitment maneuvers. So again, substantial proportion did not. And only 63% said they were prone.

This data was obtained pre-pandemic. I would suspect that since the pandemic, you know, with the COVID pneumonia and COVID ERDS, proning became so much more commonplace that I would suspect or hope that there's a little bit more implementation of this practice. But I'll speak a little more about prone positioning soon. And 47% said that they would even consider ECMO in a brain injured patient. There was another analysis of looking at three trials, larger trials, that looked at mechanical ventilation practices between 2004, 2010, and 2016, and found an increased uptake in people being willing to use unprotected ventilation, low-time volume ventilation, and also total duration. There was also significant increase in the use of just pressure support ventilation in a brain injured population.

However, no difference is now committed. Here's an interesting study recently. It was a sub-analysis, again, left by Kiara Robba. To the left are my kids in Ireland, and they changed the phone booth to defibrillators, which is pretty awesome. My kids thought it was fun. But yeah, so this is a secondary analysis of the TTM2 trial, just looking at various vent parameters and how they may have influenced outcomes. And the respiratory rate and driving pressure were the two parameters that were associated with six-month mortality, as well as neurological outcomes. There was also the mechanical power was looked at. Mechanical power is thought to be this variable that is basically a composite variable incorporating various vent parameters. And Gattinoni had put this forward, kind of hypothesizing that ventilator-induced lung injury.

is actually not just driven by just the tide volumes or just the rate or just the PEEP, but it's actually, they derived this formula basically as a composite value. That's a surrogate of the whole energy delivered to the respiratory system by the ventilator. And so in the study, they looked at mechanical power, which was associated with six-month mortality. There's also a composite formula that was basically derived from an ARDS cohort that reflected the elastic components and the more kind of dynamic components of mechanical power and showed that these were kind of in a mediation analysis, the factors that were most relevant within all event parameters. And that was also associated with both mortality and neurological outcome. So just some of our own data and a shameless self-plug. So we actually...

looked at the ENIO study. It's an extubation cord study, which I'll go into a little later when I speak about that. But we actually looked at the mechanical power. And this study collected VENT variables, ABG, you know, VENT parameters at hospital day one, three, and seven. And so we looked at these power values and looked at various outcomes, hospital mortality, reintubation, tracheostomy, and developing ARDS.

Actually, mechanical power was, at various time points, associated with all of these outcomes. But associations were the strongest on Hospital A1, which was actually surprising. We didn't suspect that, especially in the brain injury cohort. And between Hospital A1 and 3, the characteristics of the cohort was pretty similar. The patients were included for each analysis. However, there were a ton of patients that were activated between Hospital A1 and 3 that, you know, are probably patients that got intubated initially for a procedure or, you know, had hydrocephalus that got better or, you know, just got excavated quickly. But mechanical power in all of these was...

predictive of hospital mortality, actually also ICU mortality and reintubation, which was interesting. The trait part may be not as interesting because that may have been selection. Again, this is prospective observational data, so conclusions about causality is somewhat limited. The thresholds in general also, so there are studies looking at mechanical power in the general critical care population, which suggested an injurious threshold, a potentially injurious threshold, around 17 joules, whereas for brain injury populations, actually even at lower thresholds. And that surprised us, especially since the other cohorts in ICU population are ARDS cohorts. And so one thought process may be that those ARDS cohorts were just sicker and their lungs were already pretty injured and they were going to do badly anyway. I think...

Another question is, are there any brain-lung interactions, and is the brain just kind of, an injured brain kind of more susceptible, and would it mediate ventilator or lung injury at even lower thresholds? But again, it's very hard to kind of jump to causal conclusions here and randomized control data as needed. We actually did a little bit of a mediation analysis, and we actually looked at each single vent parameter and among these driving pressure, looking at tidal volume P, driving pressure, P-plats. looking at all these end parameters, and respiratory rate driving pressure was the one with the strongest association with outcomes. So we haven't published that yet, but there is another paper coming that shows the driving pressure at various time points. And again, at lower thresholds than the 15 that was shown in the Amado paper, in their mediation analysis, driving pressure emerged as a key determinant of outcome, independent of tidal volumes and compliance. We also adjusted for compliance and found that driving pressure emerged as a strong variable. However, it was only significant starting at hospital rate 3. So this mechanical power seemed to kind of pick up something earlier than that. And more on that to come soon, we're actually working on that. In general, what's needed is addition.

Just looking at kind of hospital-based outcomes, long-term neurologic outcomes, really patient-family-centric outcomes, and the reasons for these outcomes. And again, a lot of that data comes from prospective observational studies. So randomized central trials at some point I needed. What I always shook my head about before I worked on this particular paper is that in many of these trials, we just throw together brain injury. I think to any neurologist, an ischemic stroke is not the same as a TBI, is not the same as a subarachnid hemorrhage or a cardiac arrest patient. Those are very different populations. And we actually try to analyze, but it's often hard.

You lose a lot of statistical power because a lot of the ventilator models, you know, have all the ABG parameters, several markers of disease severity. And, you know, it's just easier to have a bigger sample. And there's some commonalities. But ideally, you compare how subtypes of severe acute brain injury would do. And then it would be really interesting to just directly compare thresholds in acute brain injury versus other populations using similar boards and methodology, time and circumstances and adjusting all that. And then just looking at the impact of mechanical ventilation parameters in ICP and ICP management and not just looking at kind of daily values. A lot of these large studies have collected daily value on parameters in ICP. And as we all know, there's so much dynamic stuff happening in ICP patients.

both in terms of SAP fluctuations as well as event adjustments. And then just assess more. concretely assess long, low-tidal volume ventilation and severe acute brain injury. And there's some trials underway showing that, I think, a very exciting trial that's on the horizon is the VentiBrain study, and they currently have collected the data. It's about 3,000 patients from, I think, 70 different institutions, or I think actually a little more, with mixed types of acute brain injury. And it's another prospective observational study. It looks at VENT parameters, including modes, setting, ABG values, but also things like the chest X-ray, volume status, and then other markers of just systemic disease injury, kidney injury, and all of that. And then ICP-CPP values, therapy intensity levels, and things that are done to treat the ICP, and looks at that for every day of mechanical ventilation. It includes six-month outcomes.

So it'll be a very interesting study. And I think there'll be a lot of different data coming out of that. And if anyone's interested in working that more, there's several U.S. contributors. We're actually, we were one of the sites. And on the right is the study team that contributed from Harborview. There's three studies mentions coming out. There's another study looking at SpO2 kind of goals, ProLobby, and another study actually now investigating protective tidal volumes.

Jumping to cases, a real-life case that we cared for a couple of years ago in our unit, it's a 32-year-old man who fell off a cliff. He was hiking at Hurricane Ridge in the Olympic Peninsula, and it's a beautiful picture of it. He came with a relatively small occipital bifrontal contusion that's blossomed. He actually didn't have the largest amount of DI, but he developed a lot of cerebral edema and ICP issues. He also had fractures, and he had a C2 fracture in his place in the collar. Because of poor exam, he had a Lycox port placed, his intracranial pressures were elevated, and he had a ton of pupillary changes. He actually never required a cranny, but he got a ton of doses of hypersonal therapy and was sedated and actually also got neuromuscular blockade for his ICPs around hospital day five.

He was known to have increased secretions. And the thing was, he also had neuromuscular blockade for several days. And so the RTs kept coming to us saying, we're really not getting anything up. The secretions are really thick, but they're really deep. And they're kind of worried that the neuromuscular blockade is kind of, you know, not helping with clearance of the secretions. He was found to have an MSSA pneumonia, ended up on two vasopressors, went to septic shock, and then at some point had a PDF ratio of 62, sorry, PO2 62 and 100% FY2.

His pee was tetrared up to 12. His compliance was really poor. We went down to 60 cc per kick, and his plaits were still really high. And he had the ICP monitor in. And because he was so sick and was both hypoxemic and hypercarbic respiratory failure, we had no room to go on his tidal volumes. The ECMO team actually stormed into the bedside. And my colleague, Dr. Chesnett, Randy Chesnett, one of the neurosurgeons, trauma neurosurgeons here, who's done a lot of trials and ICP monitoring. And his trial is actually done in Bolivia and Ecuador. And he's the man that did the trials, but he's also someone that just likes to come to the bedside and pull the monitor. And I remember he wanted to pull the monitor.

We're talking about proning the patient. And whenever I've prone patients with severe acute brain injury, I always find I really need to talk to my team. Because there's anything ICU is such a team sport. But there's always tons of concerns from team members that are very valid. So what about the ICU corner? Could it fall out? What's going to happen with the ICU piece? Will they be very high? And this guy was in a C collar. And that was a huge concern. And there were a lot of conversations. And the nursery team actually kept telling us ortho is on for spine. So please talk to them. Like, you're here. We need to prone the patient. And then our trauma ICU nurses told us we can't prone in the collar. And it went back and forth. I would love to hear about your experiences on that. And, you know, ideally, you don't want to have these discussions for two or three hours. You just want to prone the patient. And Randy Chesna wanted to take the monitor out because he was like,

bad for the brain too. And, you know, what are you going to do? Are you going to supinate him? SCPs go up? And I was kind of like, I want to know. I want to maybe, you know, I also was really interested, but, you know, I want to, you know, treat it. If I see it, I may, you know, treat with hyperselotherapy, do other things about it. But yeah, anyway, so we did end up running him, but more on that later. There's also another super interesting case. I saw a 41-year-old woman, actually dismay, history of polysubstance abuse. She collapsed and no one was actually really sure whether she actually arrested or was falseless, but she got bystander CPR for a little bit and then was found to have a ruptured aneurysm. I'll show her imaging here. It's a ruptured ACOM aneurysm, hydrocephalus. She had an EVD place. She went

Bay Leslie Mosby, who some of you may know, I know Nick knows, but he's one of my colleagues here and actually a chair of neurology. And he was saying that he's seen it due to a pressure effect on the stalk. But this patient went to severe DI, just dumping urine. Her sodium shot up. And, you know, initially, TCDs were flat. You know, she was given some fluid replacement. And then as he corrected the sodium, her ICP became more elevated. And then she got a fair amount of fluids. Endocrine got involved and, like, you know, was trying to correct the DI. And I think we probably overshot a little on the fluids. She had a lot of endosynchrony issues. And that was thought to be due to her needing a high amount of pain medications and probably having high tolerance towards sedation, was eventually heavily sedated. And then simultaneously, her Lindegard's ratios shot up. She had Lindegard's ratios at some point actually above.

And high peak velocities, high concern for vasospasm. At the same time, it was just dumping urine. It had also gotten volume overloaded at that time. It was a little bit of a mess. And then had a pediatric ratio of 70 to 80s. And with her, it was actually interesting because we put her on LPV. It didn't really help. It didn't really improve her oxygenation. Her plaits were actually never that bad. But when we put her on LPV, her ICPs actually became elevated because her PCO2 went up. And she had ICP issues all along. And her ICPs were also peep sensitive. We tried to titrate the peep. And we found that her best peep, according to the PB loop maneuver, was actually 14. But when we raised it, actually, her oxygenation got worse. She got hemodynamically more unstable. And her ICPs shot up to the high 30s.

We eventually did prone her. And it was interesting because my fellow kept saying that her ICPs actually, every time when we prone her, went up with some treatment and some CSF aversion and some positioning, actually, she got better. And more on that later. But I remember the fellow kept calling me and saying, when I turn her head to the right, the ICPs are really high. And when I turn her arm this way, they go up. But when I turn her head to the left and pull her arm this way, they go down. And so I didn't know what to make of that. I said, OK, then turn her head to the left, please. But yes, we did prone her. It was interesting that her chest x-ray didn't look too bad. She definitely at some point was a little volume overloaded. And it looks fluffy. It is maybe a little bit.

I moved that CT is overlaying the margin, the angle of it. It was a little bit of a floral fusion, maybe. She definitely, we did a chest CT to also look for P in other causes. And she had a lot of ground glass and a lot of kind of, you know, air bronchograms and just multifocal aspirations. Probably had just multifocal pneumonia, but it was technically not ARDS. It was a little bit weird to prone her, but her oxygenation was just super and we were kind of desperate. And so we did it.

More on that soon. Here are two reviews that some of our trainees have written. And the one on the left corner I want to point out is one with almost all female authors. And it was based on a neurocritical care society's women in neurocritical care group texting during the COVID pandemic and saying, gee, I have this patient with COVID and ARDS, and they also have EBD, and then do you guys throw them, and what do you do? And this is a group of neurointensivists from, I want to say, 11 different institutions that got together and compared their cases and put this together for tests. And then on the right, this is a review that one of our fellows wrote to see a teen. She's not the Barrow. And she did a wonderful job talking about the evidence and contrasting the evidence in the ICU population or ICU population.

Kazra Sarhadi, one of our residents, made this figure, but this is a nice figure looking at brain-lung interactions, and there's a lot of clinical and, you know, kind of macro, as well as a lot of molecular mechanisms. And I think there's a lot of kind of interaction both ways about inflammation, neuroinflammation and systemic inflammation, and with blood-brain barrier disruptions to brain-lung affect each other. There's also just elevated ICP, you know, and also in general, just sympathetic activation, sympathetic hyperactivity, influenced the capillary alveolar membrane, and it's thought to cause this entity called neurogenic form redeema. There's always a lot of debate about how it's a separate entity from ERDS, and there's a lot of animal research and pathophist studies that are very cool about that. I think ultimately it acts like ARDS to be treated or managed it like ARDS. There's also hormonal mechanisms. And then in general, just with, you know, decreased respiratory drive, worse airway protection is just high risk of aspiration, pneumonia, atelectasis, and gas exchange. And there's so many commonalities. And when you look at patients with ARDS without known brain injury, a lot of them have long-term cognitive deficits, mood disorders. Some of that may just be, you know, especially in the COVID context, there may be some direct effect from that. But I think a lot of it is also just, there's so many confounders in really knowing what causes these kind of longer-term cognitive deficits. But I think certainly a lot of...

common ICU issues, like polypharmacy, delirium fever, you know, being hypertensive, being sedated, like none of that probably helps. I think it's very complex to really discern why that is. So yes, talking about the brain lung conflict. So what is different in patients with ARDS that have severe acute brain injury versus not? So I think, again, I'll say this throughout like a broken record, but it's a constant concern for elevated ICP. With LPP titration, trying to optimize driving pressure, prone positioning, and ECMO for various reasons that I'll go into. Again, no one really knows what the best PO2 goals are for brain injury and presumably a little higher. But again, just cranking up the FI2 is also not a satisfying solution at this point. Sedation or muscular blockade, if needed, for event synchrony and to really help comply and make sure LPP is happening. Can loss can help contribute to losing the neuro exam. So it depends on how concerned you are about certain features of that. And then there's just all these logistical concerns that I mentioned with.

and positioning and what about the ICP monitor and this and that and the collar and all of that. The volume status management is always an area because, you know, for any lung injury, you want to say dry lungs or happy lungs. But there are cases such as someone's cerebral vasospasm or someone that has a fresh large vessel occlusion where aggressive iresis may be harmful. And then there's always kind of talks about using steroids. Steroids have become more of a thing in ARDS, especially since the COVID area and also next to ARDS. But there's not great data in brain injury.

I guess starting out here. So lung protective ventilation, the main concern is the permissive hypercapnia. And the low pH can also contribute to just elevating cerebral blood flow, increasing ICPs. And again, the concerns about sedation PO2. The ARMA trial excluded patients with elevated ICPs. What I would say, though, that in the ARMA trial, ARMA compared 4 to 6 cc versus 10 to 12 cc, so what's kind of the key mark trial that found mortality benefit. If you look at the 4 to 6 cc group, the PSCO2s were actually not that high. They were actually kind of in the mid-40s, so not scandalous. I would say subsequently, because there was found to be benefit, we now tolerate permissive hypercapnia. Traditionally, neurological patients, because of that, were actually often ventilated with higher tidal.

volumes because of the sphere, but there have been subsequent studies. There was a bigger one by Eva Tejerina that showed that higher tidal volumes were associated with poor outcomes and also associated with development in ARDS, not surprisingly. And I think a lot of times there were these traditional thoughts, but the wider scale data seems to suggest that withholding these therapies is not beneficial, that we should act as in any other patients. But again, there may be individual patients that are on the brink of phreniating that may need a little bit more attention to the ICP. There was a recent randomized control trial looking at 27 patients, and they were just ventilated with six cc per kick for body weight with different levels of PEEP. They had minimal ICP elevations overall, and the transformatory driving pressure was also 5-ish for both groups.

almost one in five or a little more than one in five required interruptions for ICP elevations. And those were the ones that higher mechanical power on high baseline ICPs to begin with. Potential solutions, I think it's all risk benefit. I'm going to dance around potential solutions because we still don't really know, to be honest. But in general, we aim for a PC2. I think it's just important to be aware of the PC2 and be very deliberate. And if LPD is needed from an oxygenation standpoint, it can be done. I think there's always that thought about trying to keep the PC2 okay by then compensating, cranking up the respiratory rate. And I think that...

mechanical power studies kind of hint that that's maybe not the best solution. And there are studies, and again, high respiratory rate may be an indicator of disease severity, but it's not always thought to be the solution, but it is something that can be done if the PCO2 otherwise really can't be controlled. I think in my mind, I also always see what the patient's compliance is. So the patients that I presented, the first patient really needed the lower tidal volume, so we couldn't touch the tidal volumes because the plats would just, you know, go up. There are some patients that have a little bit of room on their compliance where you could kind of play around with it and try to find, you know, a medium happy range with tidal volumes as low as possible. I think in patients where really there are concerns, there are pulmonary changes, there's a scan suggesting it, there's, you know, it's the patient at the right time window, we always have a swab.

window and TBI, ischemic stroke, hemorrhage. And if they're in that critical window and there's a concerning scan, I think that's when a monitor may be worth it. And I'll show a patient in a moment on ECMO where we put a monitor in that actually tolerated PSO2s higher than we thought. PSO2s in the 50s or 60s, but the ICP was actually fine. You know, all direct studies can also be helpful in seeing, you know, what the ICP kind of, you know, ranges and, you know, and then augmenting the MAP to really preserve CPP. But I think that, you know, in some patients, you know, I'm not always for monitoring, but in patients where you don't have an exam, where you really have bad ARDS, you need to utilize tidal volumes to the point that your PSO2s will be high, that are also at risk for radiating, that may be something we consider a monitor.

PEEP titration. There's a lot of very weird mixed data, but I think the rationale is that with increased anthropomorphic pressure and also decreased jugular venous outflow, you have elevated ICPs. And then the PEEP can also, obviously, by reducing MAP, decrease CPP. Studies are mostly small. It's mostly, you know, it's a lot of animal studies that show that, you know, PEEP can increase ICP and recruitment maneuver scan. The clinical studies that were done are mostly, you know, patients are kind of on a range of the teens, 20s at the most. They're mixed types of brain injuries. The PEEP was often just taken up to 12, and I think in a few studies of 15, which, you know, yeah, 15 is decent, but again, it's not the highest PEEP, so people have been adequately cautious. And the results are mixed. A lot of them do show that there's an effect on ICP. Some show that there is.

isn't. A few studies showed that the effect on ICP and CPP was mostly MAP-dependent. So if MAP was preserved, then usually CPP was preserved. And it also showed that especially when cerebral autoregulation was impaired, the CPP tended to be more affected. It was also found that especially when there was, you know, low compliance or alveolar hyperinflation, there's some very cool studies looking at the static, the pressure volume curves and looking at that and then seeing if the ICP is actually responsive. And there seem to be some correlations there. But again, they're very small studies. I think what's really important is, you know, as we do in any patient, but very deliberate TPP titration, especially if there's concern for elevated ICP. So we don't just kind of empirically like titrate it, but what we use kind of, you know, our balloon or other maneuvers and, you know, also look at the driving pressure and really...

avoid hyperinflation, and really preserve the map. Kara Rabat published some really cool combined brain-lung ultrasound studies. So she did lung ultrasound and TCDs of the brain or optic nerve sheath diameter and kind of looked at changes and also actually developed a lung ultrasound score to predict how much PEEP's going to affect ICP. But again, all small studies, more data is needed. Prone positioning, I talked a little about just the decreased head of bed, increased abdominal pressure, decreased outflow as higher ICPs, and then all the logistical concerns. Perceva also excluded patients with elevated ICPs. And in acute brain injury, there's a number of small studies. Again, they're all kind of smaller, mixed brain injury cord. The proning duration is very short, and some might remember there were many studies, proning trials before, Perceva that were negative, that had much

shorter proning durations. So the question is, is there even a point in proning someone for four hours or so? But none of them even got close to the 16 hours in perceiva. And there's just really no long-term outcomes. So I think what you see in those studies is, yes, when you're prone to someone, the ICP and CPP changes. And it actually kind of goes along with what I've observed. But if you look at the studies that usually, when they describe timeframes, they say usually the ICP goes up immediately when you're prone and is up for a few hours and at some point comes down or can be treated. But yes, there's ICP changes. There's sometimes pretty substantial CPP changes seen. But you also see an almost imminent improvement, pretty substantial improvement in oxygenation. And when it was measured, also PBTO2. So it seems like there's a trade-off. And again, there's no studies really showing how all of this affects.

long-term outcomes in general. I mean, usually we don't, nobody prones for fun. Usually if you're prone to patient, you have tried all of your other things. And so usually I think it's worth an attempt. You know, the question is whether you put an ICP monitor in or not. And I think my argument would be, it's nice to see the physiology. And I think you could also treat with other measures to decompress, you know, another compartment in the brain and just, you know, treat the ICPs or, you know, you can then kind of augment the maps to, you know, tighter to CPPs, but we don't really know.

you know, offloading abdominal pressure, you know, with weights, with, you know, good bowel regimen. And then sometimes if you really think you're really can't prone or you're really concerned, a patient is super unstable or there's just contraindications, supine chest compressions with weights is also an alternative. There was a cool paper in critical care medicine, a really neat one from a couple of years ago. It had very nicely summarized the different studies. And again, you can see the ICP values and then, you know, how maps changed and then also oxygenation changed. And that study, in addition to doing a systematic review and showing all the studies, then also put forward a proposed proning protocol for brain injury patients and kind of encouraged providers to consider it, but with various caveats.

So this and the images up here, the cartoons are provided by my kids, my five, my six-year-old daughter. The scans here show a patient that... had ERDS. She was a young lady that had pancreatitis and aspirated and got bad ERDS. And her PCO2 was in the 115s. And she was transferred to us, put on ECMO. The PCO2 was very rapidly corrected. And probably that caused some basic constriction and almost kind of venous-looking hemorrhage. The scan on the left was the initial one. And you can see she has very little sulci. And she actually blew both pupils. But her pupils came back after getting her menthol. And she was very hemodynamically unstable. So no neurosurgeon wanted to take her to the OR. So we actually put in an ICP monitor and medically managed her ICPs. And she actually, after a few days, got a lot better, which is super interesting.

Concerns in general, and this patient actually had a FEMFEM configuration, but large neck cannulus, fluctuations in PCO2 that can cause rapid basic constriction, ischemia, or vasodilitation, and other concerns also if someone has an ICH, usually anticoagulate. The data, and traditionally, I think often there was hesitation to put patients with severe acute brain injury on ECMO because of the presumed prognosis and the combined disease severity, but there are more and more case reports, and now pediatric case reports of someone's been cranied, child's been cranied on ECMO, and better outcomes and treatments are reported as it's utilized more, but I think it's still a very dicey area that probably requires a multidisciplinary team and very careful prognostic evaluation cases like that. case. I can say that there was a consultant that saw this case above and wrote optimized for brain death evaluation. And so I think it's just the providers with experience that look at these cases in once. And I think for us, actually, what we witnessed, this was a case in the MICU and the neurosurgeons who consulted on this were just totally scared by the ECMO, whereas actually the RDS kind of was getting better, but they were just terrified by the vasopressis, the ECMO, by everything. And I think the medical ICU providers were really concerned about the bone pupils. And so I think just that's kind of where, you know, neurointensivists, you know, general intensivists and ECMO team put their heads together. And that's usually when good decisions can be made, in my experience. Just avoid very rapid sweet gas titration. And then in patients where it's concerned for ICP, you go with a femfem cannula.

And there's a lot of technological advances with ECMO and heparin-bonded circuits that allow us to transiently run patients without anticoagulation. Volume management, I spoke about a little earlier, just volume below the pulmonary edema, just volume contributing to lung injury. And it's funny when our neurocritical care fellows go and rotate in the unit in the MICU, they always come back and diarese everybody. They are slow diaresis happy. And I have to sometimes tell them, like, oh, easy, it's supposed to be as bad as a baby. And the truth is, we don't know. I would say, actually, there are data. There's, for example, in TBI, there's big data out of Central TBI, a recent study that showed that TBB, higher positive volume balance, was associated with increased mortality. There's also a lot of studies that look at hypovolemia or actually more hypotension. And so I think that is the problem. I think we still don't have a magic way of perfectly assessing volume status. If you look at a lot of these studies, I guess, both hyper and hypo appear to be bad. The way that

measured was often by TBB or blood pressures. And there's not a lot of kind of, you know, again, it's challenging to determine critically ill patient's volume status and really put that, you know, translate that into, you know, higher volume data. But both appear to be bad. I think in general, I always think about when a critical time, you know, so for example, the vasospasm window between day four and 10, you know, you know, you get other data points to see, you know, how much at risk is this patient and it's always risk and benefit. And those are patients where I make my team, you know, do point of care ultrasound, you know, we measure our PPVs. I have to admit I'm old enough that sometimes you won't look at a CVP still, but you know, where you, you know, you get your experience, you get all of your data, your...

you know, and your clinical impression and put that puzzle together and really try to maintain intravascular uvolemia. And, you know, ideally don't shoot too high, but also are a little bit less aggressive about diuresis at least for a certain time window. Likely, this is, again, an individualized target and things like CTA, CT, perfusion, TCD could help to kind of stratify patients. Steroids. There have been actually a lot of kind of older trials looking at steroids in various forms of acute brain injury. And in ICH, acute ischemic stroke, they're not thought to be beneficial. And subarachnid hemorrhage, there's some data around vasospasm, naturesis. But again, it's kind of low-weak data. I would say that some of these trials did show higher medical side effects. And I think also extrapolating from the NASIS trials that showed in spinal cord injury, those steroids were associated with medical side effects of various kinds. Steroids are usually, they're used in actually some kinds of brain injuries, vasogenic edema with brain tumors, meningitis, but not in the kind of, you know, cytotoxic edema or acute brain injury. There was actually made up.

analysis showing some benefits in TBI. And that meta-analysis was then kiboshed by a huge trial MRC crash. Then there was a new meta-analysis and MRC crash data swayed the data towards a bad outcome. But there was actually mortality benefit seen in a prior meta-analysis. But there was this MRC crash, it's a very large data set that showed the higher mortality with hydosteroids in TBI. And so it's one of the few grade one recommendations that we have in the brain trauma foundation guidelines is to not use hydosteroids in TBI. This was acute across all GCSs. And I don't know, I feel like the problem with TBI is there's always these large trials, they always stratify by GCS, but a low GCS can be due to various mechanisms, including DAI, vasogenic edema with a contusion.

And so I think, you know, unfortunately it wasn't stratified by that. ARDS, there were actually numerous negative trials for steroids, but then DEXA ARDS right before COVID was a positive trial. And then there was a recovery trial and, you know, a meta-analysis of multiple trials in COVID. And COVID ARDS steroids became more commonplace. And there's all these trials about steroids and shock with some benefits here and there that, you know, mixed results. And I'm sure you guys can dissect or have already dissected very much in detail. In general, the problem I think is there's ARDS is not one thing. It's probably a whole umbrella of top populations in different hypo and hyper-inflammatory forms. You know, if someone has like a bad fungal pneumonia, do you have steroids there or not? And I think the same is true for brain injury. And so I think in general.

I would probably avoid them in brain injury patients, especially in TBI. But there's always, you know, risks and benefits. If someone is horribly really insufficient and in septic shock and has a COVID pneumonia and a very mild TBI, you know, it has to be little case by case. So in general, always consider risk of elevated ICP. Recess the risks and benefits over time. I think that's always key because I think things are dynamic. And, you know, one thing gets better, either the longer the brain injury and you have to just kind of just reassess your plans and confuse the trainees you work on with. You have to benefit, balance the benefits of sedation or muscular blockade, such as Venn's synchrony, with how much you want certain parts of your exam. Consider, and I would say consider invasive and non-devasive monitoring. There was just a larger study that showed a prospective observation.

study that, you know, there were some, you know, not a great outcome benefit and that there were some, you know, a lot of kind of side effects, more sedation, more ICU length of stay with invasive monitoring. But utilize them. You know, I always tell our trainees, order study, if it's going to change your management and tell me what you're going to do about it. I think specifically if you have a concern around things like the PEEP or so, that's where you can kind of utilize them to get a little more information. What we do with that data is also unfortunately not always clear. Again, consider high POTU targets, but we're with hyperoxia.

PEEP or LPV, just, you know, think about the PCO2, think about ICP, talked about prone positioning and ECMO, and then just daily multimodal volume status assessments and void steroids. In general, I would say not all acute brain injuries are equal. I think in TDI, we really think about CPP and ICP goals based on the brain trauma foundation guidelines and really, you know, this tiered approach. And subarachnoid hemorrhage after the initial stages of reuption hydrocephalus, I think in lung injury, you always think about risk of vasospasm and DCI, but there's also patients that have neurogenic cardiomyopathy. And so I think you really need to think about the volume status and blood pressure goals. In acute ischemic stroke, you want to think of the presence of especially proximal vasculostinosis occlusions, whether someone was reperfused or not, or recanalized, sorry, recanalized after the probectomy.

what the risk for reperfusion injury. And ICH is mainly about, you know, you want to monitor the exam for things like ICH expansion, hydrocephalus, herniation, you know, especially patients with IVH or patients have a big, big ICH and you need to think about how to monitor your neurologic exam. And then, and cardiac arrest, cardiac arrest and ARDS has a huge overlap. And I think up to half of those patients get some form of ARDS based on studies that you look at and, you know, cerebral edema in that context and concern for that. And, you know, we don't monitor traditionally as we do for TBI and, you know, and doing that in parallel with your neuroprote tests and as a patient gets more unstable, they may not be able to travel to MRI, you know, get, you know, we sometimes do LPs here. And so I think just kind of balancing that.

wrapping up our cases. So case number one, we actually did prone him in a C-collar. Back down here is one of our APPs who's amazing, Radha, who found a massage pillow somewhere in the nursing office. And we actually put her in a C-collar and prone her and tried it all out on her. And then we prone the patient between ortho and nurse surgery. At some point, I lost him and I paged everyone and everyone came. And we prone him with, I think, three surgeons holding him in midline. And every time he was prone and supinated, there was a provider that came from nurse surgery orthopedics. We had to prone him three times. He actually dramatically improved right after proning.

And actually with him, it was felt that also after we stopped the neuromuscular blockade, the drainage of secretions also got much better. And some of it was thought that just kind of better drainage of secretions was all that kind of stuff stuck in his lungs. His ICPs were initially elevated and responded to a lot of treatment. His monitor was eventually removed. He was excavated a few days later, and he's actually back to work. He's a biomedical engineer. The second case, she actually, this lady, went to bad vasospasm. We got two angiograms, treated with a milrinone. And we actually tried to, it was interesting because we tried to keep her volume status even, but we actually, in the vasospasm period, let it run a little more on the positive side. Very initially, when she became volume overloaded, we actually didn't diurese her, but we just held her vasopressin because she was in bad DI. We kind of let some volume out.

Her oxygenation eventually improved, and she got excavated, and she made it so well. Her ICPs remained elevated. And remember when I told you that the fellow was telling me, yeah, when we turn our head this way, her ICP goes up. And at some point, we got a neck ultrasound, and she had a large right IJ thrombus. So kudos to that fellow for being so observant. Listen to your trainees, and listen to the little details, and sometimes they matter. We started on anticoagulation, and then we got a head CT just to make sure we're anticoagulating her, what's happening here. When looking at a head CT, unfortunately, she actually had developed bilateral ACA strokes. And these were areas that actually in the prior CT perfusion were lighting up, and she actually had been placid. And I would say this must have happened between an angio. Unfortunately, she had a very poor exam to follow, and I sometimes wonder if I should have pushed for the repeated angios. But she went to ang

didn't look so bad. She got, you know, treated, but in the next subsequent days, must have developed those strokes. She's actually now somewhat better. She's alert. She tracks. She follows some commands. She's a little spastic and weak on the right side and intimately talks, but, you know, it's very abuelic and takes a long time and took a long time to recover. All right, I'm going to jump to the last very brief part, excavation trait decisions. I think the honest answer is there's still a lot of uncertainty. There's a lot of variation, you know.

predicting extubation should we try to extubate this person? It goes straight to trach. You know, the timing, when should we do it? Is it earlier better? Is it better to wait? And then, you know, what outcomes can we expect as we have these conversations? And in general, whereas neuroIC patients in general are not as commonly vented. In vented neuroIC patients, trach rates are higher. And that's because the need for trach is often due to impaired air protection in the context of decreased level of consciousness. And it's a surrogate of the severity of the brain injury. In my mind, it's often the third critical decision point and an opportunity to really revisit goals of care. I think the first one being in the ER, someone needs a crash trainee or an EVDR in life or death intervention. And those are often very rapid and very black and white and often in our department run by the neurosurgeons. The second one's often kind of at the 24 to 48 out mark.

hospitalized family at the time to kind of go to go home rest you know shower come together talk come in and there's a little bit more information about the patient and i think the third one usually happens kind of when we discuss life-sustaining therapy such as straight peg um In general, you know, what predicts a successful extubation? This is, again, something that one of my fellows always keeps saying, one of our fellows, you know, thinking about causes. You know, they keep brain injury, like where is it? You know, the two pro-infra-tentorial ones are more likely to fail. And, you know, for various reasons, both level of consciousness and area protection in terms of cranial nerve dysfunction. You think about the exam, and they fall in commands, and they alert. You think about the GCS, and, you know, that is a little bit controversial. I show the data about that as mixed. And the GCS, yes, matters because it is a surrogate for the nerve exam. But then you can also have GCS that's falsely low on an aphasic patient or someone with an eyelid opening apraxia. You think also not just about cause, but imminent things. So for the first week, often there's some swelling or edema or ICP issues.

us, you know, any other pulmonary causes. You assess oxygenation, ventilation, some mnemonic with coves. You know, you think about the exam, again, wakefulness, but also things like eye movements and get... cough, which are also surrogates for the eye movements that are kind of higher up in the midbrain. So, you know, closer to the reticular activating system, the midbrain pons, and then GAC cough, when you think about the respiratory drive, but also ability to kind of manage secretions. Secretion burden, certainly, especially if the secretion burden is coupled with clinical concerns for pneumonia, volume overload, and if it goes hand in hand with a poor exam. You know, you may have a little bit of a higher threshold to extubate someone with a higher secretion burden if they also have a poor exam, and then airway pregnancy. Here's a summary of some of kind of the older trials. You know, again, the extubation failure rates vary a bit based on what they defined as failure and what time frames, and also the population. But usually, you know, GCS and some trials were associated with extubation success. And some of the larger prospective studies, it was not. So there was a Boston study from Chris

looking at patients, and they looked at these four commands, closing eyes, two fingers, wiggling toes, and having a cough. There's a study by Godet and one by McCready that also showed that GCS was not per se, but that gag and cough were, and eye movements in one of them. And then the largest study to date is this large extubation cohort from 73 ICs in 18 countries. They looked at mixed types of brain injury, and a lower GCS, lower than 12 or equal 12 before intubation, and that were ventilated for at least 24 hours, and that did not get extubated for any terminal reasons, didn't have GBS or high C-spine injuries, or any based on major respiratory comorbidities. And they looked at extubation filled by T-5, and in general, just IC mortality. And basically, out of these patients included...

about 80% went in an excavation attempt. And out of these, a 19% failed. And this is kind of almost a little consistent with the excavation failure rates that kind of, you know, that were in the kind of teens to 20s and the prior studies also. But 19.4% failed within five days. There were only a few more that failed beyond that. And they failed to a mixed respiratory airway neurologic causes. I don't know how to discern that because in my mind, if someone gets excavated and they have a really poor nurse status and then they aspirate and get an aspiration pneumonia, was that a neurologic failure, respiratory failure, probably both additional Y variations that just reflect that, you know, there's not a clear guideline or practice on what to do or clear evidence between countries. The excavation failure rates reached between 0 and 28%. Failure was less likely in younger patients.

TBI patients, and, you know, it was higher and lower GCS. And then there was an exhibition success model. It was a 20-factor model and a simplified seven-factor model. And I listed the seven factors here. So vital signs, GAG, suctioning, swallowing attempts, visual pursuit, prophylactic PT, and the motor GCS, and GCS as well.

The 20-factor model is not particularly easy to use. And I would also say the areas under the curve are actually pretty bad for both of these models. I think not a perfect model where you should stand at the bedside and put these things at a calculator, but these are all factors that run through our head as we make these decisions. Out of the patients directly went to trach, there was higher duration of mechanical ventilation mortality compared to all extubated patients, including success and failure. But I think that is also just the nature of prospective observational trial. I think if any of us says, you know, I'm not going to extubate that patient, you know, gee, I'm just going to trach him, it's usually something that a clinician is thinking in some sort of concern or high severity. There was a follow-up study, just now some analysis of the study, looking at extubating non-invasive support for up to 24 hours and seeing if that's associated with better extubation.

success. And it wasn't. I have to say, I love high flow nasal canyon. I wish I would have invented this. But yeah, in this study, at least, it didn't show. But, you know, we talk about extubation failure and failure always implies that, you know, there was a misjudgment made. And if we think about it, 80% of these patients still passed. And I think the high failure rate just showed that we still need, you know, more information, more data on just, you know, prognosis. Looking at the flipped, there's a few clinical trach scores taking into account GCS and radiological scale, deeper location, hydrocephalus, and shift. There's also a study, just look at ICH, a clinical study that looked, COPD was an independent risk factor and things like, you know, obesity, but also just ICH volume, volume shift, all markers of...

more substantial injury. He has a set score. He used the many trials. And in terms of timing of tracheostomy and... a little bit over. Sorry, I'm going to be done in five minutes. In general, I think there's wide variations in practice, but I think a general kind of rule of thumb is like if patients still ventilated after a week and there's anticipation for longer-term mechanical ventilation, it has mixed data, controversial results, but I would say no clear evidence in favor of an early trach. The largest study in the general critical care population, trach men, did not show any differences in 30-year mortality or even two-year mortality or ICU length of stay, but it showed that 37% only longer needed a trach of patients that were randomized in a late arm. There was a meta-announce of 10 RCTs in brain injury that maybe suggested mortality benefit. It was three studies, though, that looked at longer-term mortality, and when one that was thought to be biased was excluded, that went on.

way. There was a decreased nice length of stay with early trike. And then they came to set point trial. The set point trial was a smaller single center study in RCT, 60 patients with mixed types of stroke from Germany. The primary endpoint was ICU length. Thanks to the state, I was not different. And it was actually no difference in most secondary outcomes, but there wasn't decreased a trend towards fewer opioids and a decreased knee for sedation early group. And differences in ICU mortality were found that were a little surprising. That was a small number of patients that was on withdrawal of life-sustaining treatment in the later group. But then that led to the set point two study, which Nick is actually co-author on. And so University of Maryland was the site. And this is a really excellent study. You know, what was really cool is that they really looked at patient of family centric outcomes. It was a study in Germany and US centers.

an early versus late trach. Early was, you know, in my mind, very early because that's still when a lot of, you know, evolving things like, you know, cerebral edema and, you know, and swallow watch and things like that happen. But yes, they included mixed stroke types and looked at six-month neurologic outcome as well as many, many secondary outcomes. And there's basically no difference in any of the primary major secondary endpoints. But again, 22% of the patients randomized to the later group did not require trach. Adverse events were about similar. And I would say I wasn't like that surprised by the primary outcome, although depending on how you, you know, the primary outcome was actually a modified ranking scale zero to four, which is a little different to what other trials do. And that was based on, you know, the...

It was like a PCORI grant that funded a study, and it was really like it was emphasis on patient, you know. driven outcomes. What I find really surprising is in my mind, when you trach someone, you know, you move forward, they care. If you know they need a trach, do it, right? They come off sedation, they come off the vendors. That's dead space. You know, you can mobilize them. It sounds so good. But I was actually very surprised that there were not differences in secondary points. And so I think, again, the first week's very early. I think what we know for now is, you know, waiting at least beyond the first week, you know, could get a few more people excavated. And, you know, there's not a huge downside. Some folks still say, you know, what about TBI? TBI may be a bit different because there's all these stimulation, especially in younger TBI. There's paracrysmal sympathetic hyperactivity, stimulation, ICPA issues. May some of those be better with a trach? There's still a randomized controlled data. There's a prospective registry that just...

showed wide variations. So trach rates were between 8% and 50%, early trach rate between 0% and 17%. The late trachs were associated with worse neurologic outcome. But again, this is a prospective observational study. So that may just be a marker of disease severity. And in terms of, you know, what are chances, you know, what are the outcomes when we talk about and make these decisions about whether we trach, you know, it's often, a trach is just a relatively trivial procedure, very low complication rate. I mean, if the complications happen, they're serious. But in general, it's really a bridge to...

giving a patient time and helping them achieve a neurologic outcome. And here's a few questions that I think all of you have encountered, you know, will they be a vegetable? I don't like that term, but I get asked that. You know, will they need a wheelchair? Will they be in this machine forever? And so we did a meta-analysis looking at 19 studies with a goal to look at long-term neurologic outcome. And we found 35,000 patients from 10 countries. There were only five studies reporting primary neurologic outcomes. And we try to call them as independent, dependent, and dead. And what we did find, we expected to find a lot of disabled survivors. About a third of patients and 44% of survivors were independent.

So that was interesting. However, if you think about it, you know, if you walked into a family meeting and said, you know, there's data that shows it's a meta-analysis. You know, it's obviously high estrogenity. You know, a lot of these trials for subarachnoid hemorrhage patients, a lot of these early versus late trials, where a lot of the patients that got trained early probably didn't need the trait in the first place. But still, if you walk into a family meeting and, like, quoted that, you know, anyone would jump on, you know, 30% in defense rate. But if you think about it, the majority still had a poor outcome. 36% were dependent and the remainder died. The short-term mortality was lower compared to other general critical care cohorts. And something that is valuable is 79% of survivors were eventually decannulated.

Looking back at the 7.2 study, there's actually, you know, and this is a randomized control trial, there's a fair proportion between 40 and 50% of patients that had an MRIs 4 or 5, so, you know, higher than what we found in, you know, a slightly different population. One of those studies also, there's a longer-term study that called patients actually up to two years after trach, and they found that the outcomes kind of plateaued at around a year and didn't get that much better at two or three years. They just lost patients to follow-up, and that there were differences in type of rate injury with patients with subarachnoid hemorrhage or TBI having much higher independence rate. And that's confirmed also by there's a rehab study from 29 Italian rehabs that looked at the outcomes, and patients with TBI did better than those with cerebrovascular disease. They came in the best, they improved the most, they were the least likely to die, they got out the best, and, you know improve very little at the highest mortality. And decannulation rates were kind of also a similar pattern. I'm going to end here with, we'll do one of our Stoke fellows to actually do qualitative interviews with patients that received a trach with the caveat that we didn't interview patients or families that chose against a trach. And a lot of patients were relatively young. But, you know, we interviewed them a year later about kind of the decision to pursue trach. And they said, you know, sometimes there were feelings of regret. They were very subtle often. But they often said, you know, the trach wasn't really choice. They were in that window of not knowing we had to do it. And so this prognostic uncertainty really transcended the concept of having a choice. Clear communication was always valued when present. The families reported feeling more okay with the decision regardless of the patient's outcome. So yeah.

I'm going to end here. Sorry, I ran over a little bit. In general, again, we're in a data-free zone. Just when you think about mechanical ventilation trials, often patients for injury are unrepresented. We still need to identify those who are different and what we do with them. And we still don't have good data around long-term outcomes. In general, keep things normal. Hypoxemia, hyperoxemia, hypocapnia, hypercapnia, bad. You know, consider ICPs and all kind of event parameters as listed below. And predicting successful activation just remains a challenge. There's no clear benefits of early trache and stroke. And there's still so many uncertainties in neuroprognostication that hopefully, you know, we need to shed more light on as we have these conversations with our family. Thank you very much for your time. Some of my amazing mentors, mentees, and colleagues and our amazing...

ICU team. Questions?

Beyond Hope Project with Jason Tharp Beyond Hope Project Welcome to 'Beyond Hope Project,' a beacon of inspiration in the podcast world. Join Jason Tharp as we embark on a transformative journey, exploring stories that awaken the will to start anew and find the strength to rise from setbacks. 'Beyond Hope Project' is about lighting the way to your starting line, not dictating your path. We delve into narratives that foster optimism and belief in a future where dreams become achievements. Each episode is a tapestry of positivity, enthusiasm, and comforting support, resonating with the essence of hope. This podcast goes beyond storytelling; it's a movement of positive change rooted in authenticity and transparency. We provide real tools for real journeys, infusing more hope and joy into the world. 'Beyond Hope Project' stands as a testament to the transformative power of hope and the limitless potential of the human spirit. Join us in transcending boundaries and breaking barriers. Here, we prove dai Veteran Chat Project Kyle Turner Our goal is to reach as many Veterans as we can. We noticed a lot of the podcast personalities tend to be unrelatable to the every day joe. Not taking anything away from anyone just hoping to give more people a place to feel connected to something. KZ and Kyle are Army vets who deployed together for OIF 07-09 and OND. Now close to 15 years later we are finding a way to open up about our issues, and find a way to build a community. Paramedic Philanthropy Project Melissa Ade Podcast by Melissa Ade Bigfoot Information Project Podcast Bigfoot Information Project Occasional conversations with leading researchers and investigators regarding the animal commonly referred to as bigfoot.

Frequently asked questions

How long is this episode of Maryland CC Project?

This episode is 1 hour and 1 minute long.

When was this Maryland CC Project episode published?

This episode was published on November 1, 2023.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Maryland CC Project episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.